MY
$5.76
+0.19
(+3.41%)
As of Oct 22, 2026, 9:33 PM EDT
Price history
Myriad Genetics Inc (MYGN) is trading up at $5.76 (+3.41%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Myriad Genetics Inc revenue & net income history (FY2016–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2016Jun 2016 | FY2017Jun 2017 | FY2018Jun 2018 | FY2019Jun 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $753.8M | $771.4M | $743.7M | $851.1M | $557.1M | $690.6M | $678.4M | $753.2M | $837.6M | $824.5M |
| Growth (year over year) | +4.2% | +2.3% | −3.6% | +14.4% | −34.5% | +24.0% | −1.8% | +11.0% | +11.2% | −1.6% |
| Gross profit | $621.0M | $626.2M | — | — | — | — | $476.4M | $517.0M | $585.4M | $576.6M |
| Gross margin | 82.4% | 81.2% | — | — | — | — | 70.2% | 68.6% | 69.9% | 69.9% |
| Operating income | $153.4M | $44.0M | $121.9M | $7.60M | −$289.7M | −$190.5M | −$140.6M | −$257.4M | −$123.5M | −$387.2M |
| Operating margin | 20.4% | 5.7% | 16.4% | 0.9% | −52.0% | −27.6% | −20.7% | −34.2% | −14.7% | −47.0% |
| Net income | $117.2M | $17.4M | $133.3M | $4.60M | −$223.6M | −$27.2M | −$112.0M | −$263.3M | −$127.3M | −$365.9M |
| Net margin | 15.5% | 2.3% | 17.9% | 0.5% | −40.1% | −3.9% | −16.5% | −35.0% | −15.2% | −44.4% |
| EPS (diluted) | $1.60 | $0.25 | $1.85 | $0.06 | −$2.99 | −$0.35 | −$1.39 | −$3.18 | −$1.41 | −$3.95 |
| Balance sheet | ||||||||||
| Cash and equivalents | $68.5M | $102.4M | $110.9M | $93.2M | $117.0M | $257.4M | $56.9M | $132.1M | $102.4M | $149.6M |
| Total assets | $880.5M | $1.21B | $1.18B | $1.56B | $1.42B | $1.32B | $1.20B | $1.15B | $1.03B | $706.6M |
| Total liabilities | $132.4M | $440.9M | $209.2M | $473.8M | $537.8M | $352.9M | $312.9M | $363.3M | $326.5M | $338.6M |
| Long-term debt | — | $99.1M | $9.30M | $233.5M | $224.8M | $0 | $0 | $38.5M | $39.6M | $119.9M |
| Shareholders' equity | $739.6M | $768.4M | $966.1M | $1.09B | $881.0M | $967.8M | $885.8M | $783.2M | $701.1M | $368.0M |
| Cash flow | ||||||||||
| Operating cash flow | $166.3M | $106.2M | $115.9M | $83.7M | — | $18.6M | −$106.3M | −$110.9M | −$8.70M | $1.80M |
| Capital expenditure | $5.00M | $6.10M | $8.40M | $8.60M | — | $18.0M | $45.3M | — | — | — |
| Free cash flow | $161.3M | $100.1M | $107.5M | $75.1M | — | $600.0K | −$151.6M | — | — | — |
| Share buybacks | $162.6M | $31.6M | $0 | $50.0M | — | $0 | — | — | — | — |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $213.3M | $210.6M | $195.9M | $213.1M | $205.7M | $209.8M | $200.4M | $190.7M |
| Growth (year over year) | +11.2% | +7.1% | −3.1% | +0.8% | −3.6% | −0.4% | +2.3% | −10.5% |
| Gross profit | $149.8M | $150.9M | $134.2M | $151.8M | $143.8M | $146.8M | $137.6M | $127.0M |
| Gross margin | 70.2% | 71.7% | 68.5% | 71.2% | 69.9% | 70.0% | 68.7% | 66.6% |
| Operating income | −$20.0M | −$39.1M | −$29.0M | −$329.2M | −$23.3M | −$5.70M | −$30.7M | −$38.9M |
| Operating margin | −9.4% | −18.6% | −14.8% | −154.5% | −11.3% | −2.7% | −15.3% | −20.4% |
| Net income | −$22.1M | −$42.5M | −$100.0K | −$330.5M | −$27.4M | −$7.90M | −$34.1M | −$43.2M |
| Net margin | −10.4% | −20.2% | −0.1% | −155.1% | −13.3% | −3.8% | −17.0% | −22.7% |
| EPS (diluted) | −$0.24 | −$0.47 | $0.00 | −$3.57 | −$0.29 | −$0.09 | −$0.36 | −$0.46 |
| Balance sheet | ||||||||
| Cash and equivalents | $99.9M | $102.4M | $91.8M | $74.4M | $145.4M | $149.6M | $124.4M | $115.2M |
| Total assets | $1.08B | $1.03B | $1.01B | $677.3M | $728.1M | $706.6M | $673.7M | $638.9M |
| Total liabilities | $349.6M | $326.5M | $301.2M | $289.2M | $355.3M | $338.6M | $336.3M | $335.0M |
| Long-term debt | $39.0M | $39.6M | $59.3M | $0 | $119.5M | $119.9M | $120.3M | $120.7M |
| Shareholders' equity | $731.7M | $701.1M | $704.9M | $388.1M | $372.8M | $368.0M | $337.4M | $303.9M |
| Cash flow | ||||||||
| Operating cash flow | $700.0K | $6.60M | −$16.3M | −$13.6M | $21.1M | $10.6M | −$15.7M | −$8.30M |
From Myriad Genetics Inc's 10-K, 10-KT and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Myriad Genetics Inc
- Headquarters
- Salt Lake City, Utah From SEC filings, Oct 2026
Recent News (6)
-
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
-
TD Cowen holds Myriad Genetics stock rating on Labcorp sale
TD Cowen holds Myriad Genetics stock rating on Labcorp sale
-
Myriad Genetics stock surges on $210M prenatal unit sale
Myriad Genetics stock surges on $210M prenatal unit sale
-
Why is Myriad Genetics stock surging today?
Why is Myriad Genetics stock surging today?
-
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026 Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
-
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International